DBVT News and Press, DBV Technologies S.A. From 06/08/22

Shares of the unique biotech DBV Technologies (NASDAQ: DBVT) surged nearly 20% higher on Wednesday, far outpacing many peer stocks. That's because the company had some very encouraging news to impart about its key pipeline drug. DBV is developing a patch treatment for peanut all...

Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) ...

Cyren (CYRN) +39% on €10M sale of secure email gateway unit. Redbox Entertainment (RDBX) +25%. DBV Technologies (DBVT) +19% phase 3 trial for peanut allergy treatment in toddlers meets main goal. Brenmiller Energy (BNRG) +16%. Energy Focus (EFOI) +15%. Aldeyra Thera...

3 Penny Stocks That Climbed in After Hours Trading After a mostly bullish day of trading penny stocks and blue chips, there is a lot for investors to know. Right now, we have to consider the main factors that are at play in the stock market. This includes rising inflation, and more impo...

U.S.-listed shares of DBV Technologies (NASDAQ:DBVT) soared nearly 40% to $2.14 in Tuesday aftermarket trading, after the company said its phase 3 trial assessing its Viaskin Peanut for the treatment of peanut allergies in toddlers aged 1 to 3 years met its main goal. Viaskin Peanut...

Gainers: DBV Technologies  (DBVT) +48%. Biodesix (BDSX) +15%. Intel Corporation (INTC) +7%. Limoneira (LMNR) +6%. Groupon (GRPN) +5%. Losers: Redbox Entertainment (RDBX) -5%. C4 Therapeutics (CCCC) -5%. Kezar Life Sciences (KZR) -5%. Iris Energy Limited (IREN) -5%. LumiraDx Lim...

Montrouge, France, June 7, 2022 DBV Technologies Announce s Positive Topline Results from Phase 3 EPITOPE T rial of Viaskin Peanut in Peanut - Allerg ic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µ...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE E...

Montrouge, France, May 12, 2022 DBV Technologies Announces Results of I ts 2022 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed Re solutions DBV Technologies (Euronext: DBV – ISI...

Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $ 15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “C...